A nurse is caring for a child who has a history of Kawasaki disease and was treated with immunoglobulin 4 months ago. Which vaccine should the nurse expect to administer during the annual physical exam?

This scenario requires applying knowledge of immunology and vaccine timing following the administration of blood products or immunoglobulins. Understanding how exogenous antibodies interfere with the replication of live-attenuated vaccines is crucial for ensuring effective immunization schedules in pediatric patients. Choice A rationale The rotavirus vaccine is a live-attenuated virus usually administered in early infancy. Since this child is older and having an annual exam, this vaccine is not typically indicated, regardless of the timing of the prior immunoglobulin treatment. Choice B rationale High-dose immunoglobulin treatment interferes with the immune response to the live MMR vaccine. Guidelines usually recommend delaying live vaccines for 8 to 11 months after IVIG to ensure the child can mount an appropriate endogenous antibody response. Choice C rationale The inactivated influenza vaccine does not contain live virus and is not affected by circulating antibodies from immunoglobulin therapy. It should be administered annually to children to provide protection against seasonal viral strains without requiring any delay. Choice D rationale Varicella is a live-attenuated vaccine. Similar to MMR, the exogenous antibodies from the 4-month-ago IVIG treatment will likely neutralize the vaccine virus before it can trigger a long-term immune memory, necessitating a longer delay before administration.